EA202193024A1 - Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров - Google Patents

Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров

Info

Publication number
EA202193024A1
EA202193024A1 EA202193024A EA202193024A EA202193024A1 EA 202193024 A1 EA202193024 A1 EA 202193024A1 EA 202193024 A EA202193024 A EA 202193024A EA 202193024 A EA202193024 A EA 202193024A EA 202193024 A1 EA202193024 A1 EA 202193024A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patients
therapy
limited number
natural killer
killer cells
Prior art date
Application number
EA202193024A
Other languages
English (en)
Inventor
Кристиан Куффер
Гюнтер Фингерле-Роусон
Марк Виндерлих
Ян Энделль
Original Assignee
МорфоСис АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МорфоСис АГ filed Critical МорфоСис АГ
Publication of EA202193024A1 publication Critical patent/EA202193024A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Согласно настоящему изобретению предложены характеристики и биомаркеры у пациентов, получающих лечение анти-CD19 антителами (MOR00208, XmAb5574). Кроме того, настоящее изобретение относится к анти-CD19 антителам для лечения лейкемии или лимфомы у пациентов с исходным количеством периферических NK-клеток, меньшим или равным 100 NK-клеток/мкл.
EA202193024A 2019-05-03 2020-05-04 Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров EA202193024A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19172495 2019-05-03
PCT/EP2020/062289 WO2020225196A1 (en) 2019-05-03 2020-05-04 Anti-cd19 therapy in patients having a limited number of nk cells

Publications (1)

Publication Number Publication Date
EA202193024A1 true EA202193024A1 (ru) 2022-02-09

Family

ID=66647010

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193024A EA202193024A1 (ru) 2019-05-03 2020-05-04 Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров

Country Status (13)

Country Link
US (1) US20220242952A1 (ru)
EP (1) EP3962943A1 (ru)
JP (1) JP2022532519A (ru)
KR (1) KR20220007087A (ru)
CN (1) CN114072424A (ru)
AU (1) AU2020267823A1 (ru)
CA (1) CA3137664A1 (ru)
EA (1) EA202193024A1 (ru)
IL (1) IL287203A (ru)
MA (1) MA55794A (ru)
MX (1) MX2021013101A (ru)
SG (1) SG11202111343TA (ru)
WO (1) WO2020225196A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292181A (en) * 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
CN101351477B (zh) 2005-12-30 2011-11-16 默克专利有限公司 具有降低的免疫原性的抗cd19抗体
PT2059536E (pt) 2006-08-14 2014-04-14 Xencor Inc Anticorpos otimizados que visam cd19
EP2066349B1 (en) 2006-09-08 2012-03-28 MedImmune, LLC Humanized anti-cd19 antibodies and their use in treatment of tumors, transplantation and autoimmune diseases
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
US7968687B2 (en) 2007-10-19 2011-06-28 Seattle Genetics, Inc. CD19 binding agents and uses thereof
US8679492B2 (en) 2009-02-23 2014-03-25 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to CD19 and their uses
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
HUE054860T2 (hu) * 2016-05-30 2021-10-28 Morphosys Ag Eljárás betegekben CD19 elleni ellenanyagon alapuló terápia terápiás hasznosságának elõrejelzésére

Also Published As

Publication number Publication date
SG11202111343TA (en) 2021-11-29
IL287203A (en) 2021-12-01
KR20220007087A (ko) 2022-01-18
MA55794A (fr) 2022-03-09
MX2021013101A (es) 2022-01-04
CN114072424A (zh) 2022-02-18
JP2022532519A (ja) 2022-07-15
US20220242952A1 (en) 2022-08-04
CA3137664A1 (en) 2020-11-12
WO2020225196A1 (en) 2020-11-12
EP3962943A1 (en) 2022-03-09
AU2020267823A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
EA202092243A1 (ru) Способы усиления персистенции адоптивно инфузированных т-клеток
MX2020005463A (es) Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
MX2020012028A (es) Metodos y composiciones para tratar el cancer.
WO2017214207A8 (en) Methods for the treatment of b cell malignancies using adoptive cell therapy
MY194175A (en) Variant rnai
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
MX2021006238A (es) Metodos para tratamiento que usan terapia celular adoptiva.
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
MX2022000726A (es) Anticuerpos inmunomoduladores y metodos de uso de los mismos.
PH12021550553A1 (en) Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
ZA202205927B (en) Anti-yellow fever virus antibodies, and methods of their generation and use
EA202191067A1 (ru) Композиции и способы для лечения дефицита альфа-1-антитрипсина
PH12020500664A1 (en) C3-binding agents and methods of use thereof
CY1124768T1 (el) Μεθοδος για προβλεψη θεραπευτικης ωφελειας της anti-cd19 θεραπειας σε ασθενεις
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18
ATE478076T1 (de) Azaxanthonen zur behandlung von tumoren
EA202193024A1 (ru) Анти-cd19-терапия у пациентов с ограниченным числом естественных клеток-киллеров
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
MX2021006244A (es) Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva.
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
PH12021551246A1 (en) Placenta-derived allogeneic car-t cells and uses thereof
ZA201907369B (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
BR112023018621A2 (pt) Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii